<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET>
<STUDY accession="ERP118881" alias="ena-STUDY-LIFESEQUENCING-11-12-2019-15:50:08:385-1106" center_name="LifeSequencing, Parc Cientific Universitat de Valencia, 46980 - Paterna (Valencia) SPAIN">
     <IDENTIFIERS>
          <PRIMARY_ID>ERP118881</PRIMARY_ID>
          <SECONDARY_ID>PRJEB35769</SECONDARY_ID>
          <SUBMITTER_ID namespace="LifeSequencing, Parc Cientific Universitat de Valencia, 46980 - Paterna (Valencia) SPAIN">ena-STUDY-LIFESEQUENCING-11-12-2019-15:50:08:385-1106</SUBMITTER_ID>
     </IDENTIFIERS>
     <DESCRIPTOR>
          <STUDY_TITLE>Gut microbiome response to a fermented milk product in healthy subjects</STUDY_TITLE>
          <STUDY_ABSTRACT>Although many clinical studies have been conducted to evaluate the effect of probiotics, there are limited studies that assessed the dose-response effects of probiotics on microbiota and host. In this context, a novel multi-strain fermented dairy product was developed (Test product), combining yogurt strains (Streptococcus thermophilus and Lactobacillus bulgaricus) and three candidate probiotic strains, Lactobacillus paracasei subsp. paracasei CNCM I-1518 and CNCM I-3689 and Lactobacillus rhamnosus CNCM I-3690 selected for their effects on gut barrier function and/or gut microbiota or immunity in various models. In the present study, we conducted a 4-week intervention, randomised, double-blind, controlled clinical trial to assess the tolerance of daily ingestion of one or three doses of the Test product in 96 healthy adults. We explored the structural and functional response of gut microbiota to intervention, and following discontinuation. Using shotgun metagenomic, we explored the KEGG orthologs that were carried by 3 probiotic candidate strains and their co-variation interactions with gut microbial species through metabolic sharing.</STUDY_ABSTRACT>
          <STUDY_DESCRIPTION>Although many clinical studies have been conducted to evaluate the effect of probiotics, there are limited studies that assessed the dose-response effects of probiotics on microbiota and host. In this context, a novel multi-strain fermented dairy product was developed (Test product), combining yogurt strains (Streptococcus thermophilus and Lactobacillus bulgaricus) and three candidate probiotic strains, Lactobacillus paracasei subsp. paracasei CNCM I-1518 and CNCM I-3689 and Lactobacillus rhamnosus CNCM I-3690 selected for their effects on gut barrier function and/or gut microbiota or immunity in various models. In the present study, we conducted a 4-week intervention, randomised, double-blind, controlled clinical trial to assess the tolerance of daily ingestion of one or three doses of the Test product in 96 healthy adults. We explored the structural and functional response of gut microbiota to intervention, and following discontinuation. Using shotgun metagenomic, we explored the KEGG orthologs that were carried by 3 probiotic candidate strains and their co-variation interactions with gut microbial species through metabolic sharing.</STUDY_DESCRIPTION>
          <CENTER_PROJECT_NAME>Tolerance study</CENTER_PROJECT_NAME>
          <STUDY_TYPE existing_study_type="Other"/>
     </DESCRIPTOR>
     <STUDY_LINKS>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SAMPLE</DB>
                    <ID>ERS4182283-ERS4182389,ERS4187653-ERS4188001</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-EXPERIMENT</DB>
                    <ID>ERX3766553-ERX3766659,ERX3766792-ERX3767140</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-RUN</DB>
                    <ID>ERR3764800-ERR3764906,ERR3765039-ERR3765387</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SUBMISSION</DB>
                    <ID>ERA2316646</ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-FASTQ-FILES</DB>
                    <ID><![CDATA[https://www.ebi.ac.uk/ena/portal/api/filereport?accession=ERP118881&result=read_run&fields=run_accession,fastq_ftp,fastq_md5,fastq_bytes]]></ID>
               </XREF_LINK>
          </STUDY_LINK>
          <STUDY_LINK>
               <XREF_LINK>
                    <DB>ENA-SUBMITTED-FILES</DB>
                    <ID><![CDATA[https://www.ebi.ac.uk/ena/portal/api/filereport?accession=ERP118881&result=read_run&fields=run_accession,submitted_ftp,submitted_md5,submitted_bytes,submitted_format]]></ID>
               </XREF_LINK>
          </STUDY_LINK>
     </STUDY_LINKS>
     <STUDY_ATTRIBUTES>
          <STUDY_ATTRIBUTE>
               <TAG>clinical trial</TAG>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>gut microbiome</TAG>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-SPOT-COUNT</TAG>
               <VALUE>3792117992</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-BASE-COUNT</TAG>
               <VALUE>984161147894</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-FIRST-PUBLIC</TAG>
               <VALUE>2020-09-27</VALUE>
          </STUDY_ATTRIBUTE>
          <STUDY_ATTRIBUTE>
               <TAG>ENA-LAST-UPDATE</TAG>
               <VALUE>2019-12-11</VALUE>
          </STUDY_ATTRIBUTE>
     </STUDY_ATTRIBUTES>
</STUDY>
</STUDY_SET>
